-
(
LinC
ShiX
YangS
, et al. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer. 2019;131:62-68.31027700)
LinC
ShiX
YangS
, et al. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer. 2019;131:62-68.31027700
LinC
ShiX
YangS
, et al. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer. 2019;131:62-68.31027700,
LinC
ShiX
YangS
, et al. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer. 2019;131:62-68.31027700
-
(
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.26028407)
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.26028407
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.26028407,
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.26028407
-
(
BergethonK
ShawAT
OuSH
, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.22215748)
BergethonK
ShawAT
OuSH
, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.22215748
BergethonK
ShawAT
OuSH
, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.22215748,
BergethonK
ShawAT
OuSH
, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.22215748
-
V.
Rimkunas,
K.
Crosby,
Dai-qiang
Li,
Ye-rong
Hu,
M.
Kelly,
T.
Gu,
Jennifer
Mack,
M.
Silver,
Xinmin
Zhou,
H.
Haack
(2012)
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Clinical Cancer Research, 18
-
(
MuCY
HuangJA
ChenY
ChenC
ZhangXG.
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682-688.20373055)
MuCY
HuangJA
ChenY
ChenC
ZhangXG.
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682-688.20373055
MuCY
HuangJA
ChenY
ChenC
ZhangXG.
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682-688.20373055,
MuCY
HuangJA
ChenY
ChenC
ZhangXG.
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682-688.20373055
-
P.
Tran,
P.
Bendapudi,
H.
Lin,
P.
Choi,
Shan
Koh,
Joy
Chen,
G.
Horng,
N.
Hughes,
L.
Schwartz,
V.
Miller,
T.
Kawashima,
T.
Kitamura,
D.
Paik,
D.
Felsher
(2011)
Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation
Science Translational Medicine, 3
-
T.
Mok,
Yi‐Long
Wu,
I.
Kudaba,
D.
Kowalski,
B.
Cho,
H.
Turna,
G.
Castro,
V.
Srimuninnimit,
K.
Laktionov,
I.
Bondarenko,
K.
Kubota,
G.
Lubiniecki,
Jin
Zhang,
D.
Kush,
G.
Lopes,
G.
Adamchuk,
M.
Ahn,
A.
Alexandru,
O.
Altundag,
A.
Alyasova,
O.
Andrusenko,
K.
Aoe,
A.
Araújo,
O.
Aren,
O.
Rodriguez,
T.
Ativitavas,
Oscar
Avendano,
F.
Barata,
C.
Barrios,
C.
Beato,
Per
Bergstrom,
D.
Betticher,
L.
Bolotina,
Michiel
Botha,
Sayeuri
Buddu,
C.
Caglevic,
A.
Cardona,
H.
Castro,
F.
Senler,
Carlos
Cerny,
A.
Česas,
G.
Chan,
Jian-hua
Chang,
Gongyan
Chen,
Xi
Chen,
S.
Cheng,
Ying
Cheng,
N.
Cherciu,
C.
Chiu,
S.
Cicėnas,
D.
Ciurescu,
G.
Cohen,
Marcos
Costa,
P.
Danchaivijitr,
F.
Angelis,
S.
Azevedo,
M.
Dediu,
Ts
Deliverski,
P.
Marchi,
Flor
Valles,
Z.
Ding,
Boyan
Doganov,
L.
Dreosti,
R.
Duarte,
Regina
Edusma-Dy,
S.
Emelyanov,
M.
Erman,
Yun
Fan,
L.
Fein,
Jifeng
Feng,
D.
Fenton,
G.
Fernandes,
C.
Ferreira,
F.
Franke,
H.
Freitas,
Y.
Fujisaka,
H.
Galindo,
Christina
Galvez,
D.
Ganea,
N.
Gil,
G.
Girotto,
E.
Goker,
T.
Goksel,
Gonzalo
Aubin,
Luis
Wolff,
H.
Griph,
M.
Gumus,
Jacqueline
Hall,
Greg
Hart,
L.
Havel,
Jianxing
He,
Yong
He,
C.
Hernández,
V.
Hespanhol,
T.
Hirashima,
Chung-man.
Ho,
A.
Horiike,
Y.
Hosomi,
K.
Hotta,
M.
Hou,
S.
How,
T.
Hsia,
Yi
Hu,
M.
Ichiki,
F.
Imamura,
O.
Ivashchuk,
Y.
Iwamoto,
J.
Jaal,
J.
Jassem,
Christa
Jordaan,
R.
Juergens,
D.
Kaen,
E.
Kalinka‐Warzocha,
N.
Karaseva,
B.
Karaszewska,
A.
Każarnowicz,
K.
Kasahara,
N.
Katakami,
T.
Kato,
T.
Kawaguchi,
J.
Kim,
K.
Kishi,
V.
Kolek,
Marchela
Koleva,
P.
Kolman,
L.
Koubková,
R.
Kowalyszyn,
D.
Kowalski,
K.
Koynov,
D.
Ksienski,
T.
Kurata,
G.
Kuusk,
L.
Kuzina,
I.
Laczó,
G.
Ladrera,
K.
Laktionov,
G.
Landers,
S.
Lazarev,
G.
Lerzo,
Krzysztof
Kmak,
Wei
Li,
C.
Liam,
Igor
Lifirenko,
O.
Lipatov,
Xiaoqing
Liu,
Zhe
Liu,
S.
Lo,
Valeria
Lopes,
Karla
Lopez,
Shun
Lu,
G.
Martinengo,
L.
Mas,
M.
Matrosova,
Rumyana
Micheva,
Z.
Milanova,
L.
Miron,
Tony
Mok,
M.
Molina,
S.
Murakami,
Y.
Nakahara,
Tien
Nguyen,
T.
Nishimura,
A.
Ochsenbein,
T.
Ohira,
Ronny
Ohman,
C.
Ong,
G.
Ostoros,
X.
Ouyang,
E.
Ovchinnikova,
O.
Ozyılkan,
L.
Petruželka,
Xuan
Pham,
P.
Picon,
B.
Pikó,
A.
Poltoratsky,
Olga
Ponomarova,
Patrice
Popelkova,
G.
Purkalne,
S.
Qin,
R.
Ramlau,
Bernardo
Rappaport,
Felipe
Rey,
E.
Richardet,
J.
Roubec,
P.
Ruff,
A.
Rusyn,
H.
Saka,
J.
Salas,
Mario
Sandoval,
L.
Santos,
T.
Sawa,
K.
Seetalarom,
M.
Seker,
N.
Seki,
Freddy
Seolwane,
L.
Shepherd,
Sergii
Shevnya,
A.
Shimada,
Y.
Shparyk,
I.
Sinielnikov,
D.
Sirbu,
O.
Smaletz,
João
Soares,
A.
Sookprasert,
G.
Speranza,
V.
Sriuranpong,
Zinaida
Stara,
W.
Su,
S.
Sugawara,
W.
Szpak,
Kazuhisa
Takahashi,
N.
Takigawa,
Hiroshi
Tanaka,
Jerry
Bing,
Q.
Tang,
P.
Taranov,
H.
Tejada,
L.
Tho,
Yoshitaro
Torii,
Dmytro
Trukhyn,
M.
Turdean,
H.
Turna,
G.
Ursol,
J.
Vaňásek,
M.
Varela,
M.
Vallejo,
Luis
Vera,
A.
Victorino,
T.
Vlásek,
I.
Vynnychenko,
Buhai
Wang,
Jie
Wang,
Kai
Wang,
Yilong
Wu,
Kazuhiko
Yamada,
Chih‐Hsin
Yang,
T.
Yokoyama,
T.
Yokoyama,
H.
Yoshioka,
F.
Yumuk,
A.
Zambrano,
J.
Zarbá,
O.
Zarubenkov,
Marius
Žemaitis,
Li
Zhang,
Xin
Zhang,
Jun
Zhao,
Caicun
Zhou,
Jianying
Zhou,
Qing
Zhou,
A.
Zippelius
(2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet, 393
-
(
ChinLP
SooRA
SoongR
OuSH.
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7:1625-1630.23070242)
ChinLP
SooRA
SoongR
OuSH.
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7:1625-1630.23070242
ChinLP
SooRA
SoongR
OuSH.
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7:1625-1630.23070242,
ChinLP
SooRA
SoongR
OuSH.
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7:1625-1630.23070242
-
E.
Munari,
F.
Mariotti,
L.
Quatrini,
P.
Bertoglio,
N.
Tumino,
P.
Vacca,
A.
Eccher,
F.
Ciompi,
M.
Brunelli,
G.
Martignoni,
G.
Bogina,
L.
Moretta
(2021)
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
International Journal of Molecular Sciences, 22
-
Q.
Qin,
Baosheng
Li
(2019)
Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions
Journal of Cancer Research and Therapeutics, 15
-
Changping
Wu,
Yi-bei
Zhu,
Jingting
Jiang,
Jie-Min
Zhao,
Xue-guang
Zhang,
N.
Xu
(2006)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
Acta histochemica, 108 1
-
A.
Shaw,
B.
Yeap,
M.
Mino‐Kenudson,
S.
Digumarthy,
D.
Costa,
R.
Heist,
B.
Solomon,
Hannah
Stubbs,
S.
Admane,
U.
McDermott,
J.
Settleman,
Susumu
Kobayashi,
E.
Mark,
S.
Rodig,
L.
Chirieac,
E.
Kwak,
T.
Lynch,
A.
Iafrate
(2009)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
-
N.
Leighl,
N.
Rekhtman,
W.
Biermann,
James
Huang,
M.
Mino‐Kenudson,
S.
Ramalingam,
H.
West,
Sara
Whitlock,
M.
Somerfield
(2014)
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cance
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 32
-
G.
Minuti,
A.
D’Incecco,
L.
Landi,
F.
Cappuzzo
(2014)
Protein kinase inhibitors to treat non-small-cell lung cancer
Expert Opinion on Pharmacotherapy, 15
-
(
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.26412456)
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.26412456
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.26412456,
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.26412456
-
A.
Ooi,
A.
Gower,
K.
Zhang,
Jessica
Vick,
Longsheng
Hong,
Brian
Nagao,
William
Wallace,
D.
Elashoff,
Tonya
Walser,
S.
Dubinett,
M.
Pellegrini,
M.
Lenburg,
A.
Spira,
B.
Gomperts
(2014)
Molecular Profiling of Premalignant Lesions in Lung Squamous Cell Carcinomas Identifies Mechanisms Involved in Stepwise Carcinogenesis
Cancer Prevention Research, 7
-
(
HinoR
KabashimaK
KatoY
, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-1766.20143437)
HinoR
KabashimaK
KatoY
, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-1766.20143437
HinoR
KabashimaK
KatoY
, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-1766.20143437,
HinoR
KabashimaK
KatoY
, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-1766.20143437
-
Anna
Seo,
Anna
Seo,
Yang
Jm,
H.
Kim,
H.
Kim,
S.
Jheon,
S.
Jheon,
Kwhanmien
Kim,
Kwhanmien
Kim,
Lee
Ct,
Lee
Ct,
Y.
Jin,
Y.
Jin,
S.
Yun,
S.
Yun,
Chung
Jh,
Chung
Jh,
Paik
Jh,
Paik
Jh
(2014)
Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas
British Journal of Cancer, 110
-
(
SeoAN
YangJM
KimH
, et al. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 2014;110:2688-2699.24809777)
SeoAN
YangJM
KimH
, et al. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 2014;110:2688-2699.24809777
SeoAN
YangJM
KimH
, et al. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 2014;110:2688-2699.24809777,
SeoAN
YangJM
KimH
, et al. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 2014;110:2688-2699.24809777
-
(
KimEY
KimA
KimSK
ChangYS.
MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer. 2017;110:63-67.28676221)
KimEY
KimA
KimSK
ChangYS.
MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer. 2017;110:63-67.28676221
KimEY
KimA
KimSK
ChangYS.
MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer. 2017;110:63-67.28676221,
KimEY
KimA
KimSK
ChangYS.
MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer. 2017;110:63-67.28676221
-
M.
Ilié,
V.
Hofman,
M.
Dietel,
J.
Soria,
P.
Hofman
(2016)
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Virchows Archiv, 468
-
Si
Chen,
Yingxi
Xu,
Yanan
Chen,
Xue-fei
Li,
W.
Mou,
Lina
Wang,
Yanhua
Liu,
R.
Reisfeld,
R.
Xiang,
D.
Lv,
Na
Li
(2012)
SOX2 Gene Regulates the Transcriptional Network of Oncogenes and Affects Tumorigenesis of Human Lung Cancer Cells
PLoS ONE, 7
-
Leow
Chin,
R.
Soo,
R.
Soong,
S.
Ou
(2012)
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology, 7
-
J.
Brahmer,
K.
Reckamp,
P.
Baas,
L.
Crinò,
W.
Eberhardt,
E.
Poddubskaya,
S.
Antonia,
A.
Płużański,
E.
Vokes,
E.
Holgado,
D.
Waterhouse,
N.
Ready,
J.
Gainor,
O.
Frontera,
L.
Havel,
M.
Steins,
M.
Garassino,
J.
Aerts,
M.
Dómine,
L.
Paz-Ares,
M.
Reck,
C.
Baudelet,
C.
Harbison,
B.
Lestini,
D.
Spigel
(2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 2
-
S.
Casey,
Ling
Tong,
Yulin
Li,
R.
Do,
S.
Walz,
Kelly
Fitzgerald,
A.
Gouw,
Virginie
Baylot,
I.
Gütgemann,
M.
Eilers,
D.
Felsher
(2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Science, 352
-
C.
Mu,
Jian-an
Huang,
Ying
Chen,
Cheng
Chen,
Xue-guang
Zhang
(2011)
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Medical Oncology, 28
-
H.
Kaneda,
I.
Okamoto,
K.
Nakagawa
(2013)
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8 4
-
(
ZhouC
CheG
ZhengX
, et al. Expression and clinical significance of PD‑L1 and c‑Myc in non‑small cell lung cancer. J Cancer Res Clin Oncol. 2019;145:2663-2674.31541338)
ZhouC
CheG
ZhengX
, et al. Expression and clinical significance of PD‑L1 and c‑Myc in non‑small cell lung cancer. J Cancer Res Clin Oncol. 2019;145:2663-2674.31541338
ZhouC
CheG
ZhengX
, et al. Expression and clinical significance of PD‑L1 and c‑Myc in non‑small cell lung cancer. J Cancer Res Clin Oncol. 2019;145:2663-2674.31541338,
ZhouC
CheG
ZhengX
, et al. Expression and clinical significance of PD‑L1 and c‑Myc in non‑small cell lung cancer. J Cancer Res Clin Oncol. 2019;145:2663-2674.31541338
-
A.
El-Telbany,
P.
Ma
(2012)
Cancer genes in lung cancer: racial disparities: are there any?
Genes & cancer, 3 7-8
-
(
TranPT
BendapudiPK
LinHJ
, et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med. 2011;3:103ra99.)
TranPT
BendapudiPK
LinHJ
, et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med. 2011;3:103ra99.
TranPT
BendapudiPK
LinHJ
, et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med. 2011;3:103ra99.,
TranPT
BendapudiPK
LinHJ
, et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med. 2011;3:103ra99.
-
(
WuC
ZhuY
JiangJ
ZhaoJ
ZhangXG
XuN.
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108:19-24.16530813)
WuC
ZhuY
JiangJ
ZhaoJ
ZhangXG
XuN.
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108:19-24.16530813
WuC
ZhuY
JiangJ
ZhaoJ
ZhangXG
XuN.
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108:19-24.16530813,
WuC
ZhuY
JiangJ
ZhaoJ
ZhangXG
XuN.
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108:19-24.16530813
-
(
SchmidtLH
KummelA
GorlichD
, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS ONE. 2015;10:e0136023.26313362)
SchmidtLH
KummelA
GorlichD
, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS ONE. 2015;10:e0136023.26313362
SchmidtLH
KummelA
GorlichD
, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS ONE. 2015;10:e0136023.26313362,
SchmidtLH
KummelA
GorlichD
, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS ONE. 2015;10:e0136023.26313362
-
(
MunariE
MariottiFR
QuatriniL
, et al. PD-1/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci. 2021;22:5123.34066087)
MunariE
MariottiFR
QuatriniL
, et al. PD-1/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci. 2021;22:5123.34066087
MunariE
MariottiFR
QuatriniL
, et al. PD-1/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci. 2021;22:5123.34066087,
MunariE
MariottiFR
QuatriniL
, et al. PD-1/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci. 2021;22:5123.34066087
-
N.
Rizvi,
M.
Hellmann,
A.
Snyder,
P.
Kvistborg,
V.
Makarov,
J.
Havel,
William
Lee,
Jianda
Yuan,
P.
Wong,
Teresa
Ho,
Martin
Miller,
N.
Rekhtman,
A.
Moreira,
Fawzia
Ibrahim,
Cameron
Bruggeman,
Billel
Gasmi,
R.
Zappasodi,
Y.
Maeda,
C.
Sander,
E.
Garon,
T.
Merghoub,
J.
Wolchok,
T.
Schumacher,
T.
Chan
(2015)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science, 348
-
J.
Mazières,
C.
Cropet,
L.
Montané,
F.
Barlesi,
P.
Souquet,
X.
Quantin,
C.
Dubos-Arvis,
J.
Otto,
L.
Favier,
V.
Avrillon,
J.
Cadranel,
D.
Moro-Sibilot,
I.
Monnet,
V.
Westeel,
J.
Treut,
Etienne
Brain,
Jean
Trédaniel,
M.
Jaffro,
S.
Collot,
G.
Ferretti,
C.
Tiffon,
C.
Oukhatar,
J.
Blay
(2020)
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
Annals of oncology : official journal of the European Society for Medical Oncology, 31 2
-
V.
Atsaves,
Nikolaos
Tsesmetzis,
Dimitris
Chioureas,
L.
Kis,
L.
Kis,
Vasiliki
Leventaki,
E.
Drakos,
T.
Panaretakis,
D.
Grandér,
L.
Medeiros,
K.
Young,
G.
Rassidakis,
G.
Rassidakis,
G.
Rassidakis
(2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
Leukemia, 31
-
(
GaronEB
RizviNA
HuiR
, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.25891174)
GaronEB
RizviNA
HuiR
, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.25891174
GaronEB
RizviNA
HuiR
, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.25891174,
GaronEB
RizviNA
HuiR
, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.25891174
-
K.
Takeuchi,
M.
Soda,
Yuki
Togashi,
R.
Suzuki,
S.
Sakata,
S.
Hatano,
R.
Asaka,
W.
Hamanaka,
H.
Ninomiya,
H.
Uehara,
Y.
Choi,
Y.
Satoh,
S.
Okumura,
K.
Nakagawa,
H.
Mano,
Y.
Ishikawa
(2012)
RET, ROS1 and ALK fusions in lung cancer
Nature Medicine, 18
-
(
HirschFR
SudaK
WiensJ
, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012-1024.27598681)
HirschFR
SudaK
WiensJ
, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012-1024.27598681
HirschFR
SudaK
WiensJ
, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012-1024.27598681,
HirschFR
SudaK
WiensJ
, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012-1024.27598681
-
(2015)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer.
The New England journal of medicine, 373 16
-
P.
Graziano,
G.
Cardillo,
A.
Mancuso,
G.
Paone,
R.
Gasbarra,
F.
Marinis,
A.
Leone
(2011)
Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics.
Chest, 140 5
-
S.
Peters,
D.
Camidge,
A.
Shaw,
S.
Gadgeel,
J.
Ahn,
Dong-Wan
Kim,
S.
Ou,
M.
Pérol,
R.
Dziadziuszko,
R.
Rosell,
A.
Zeaiter,
E.
Mitry,
S.
Golding,
B.
Balas,
J.
Noé,
P.
Morcos,
T.
Mok
(2017)
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 377
-
Yi-cheng
Wu,
I.
Chang,
Chi-Liang
Wang,
Tai-Di
Chen,
Ya-Ting
Chen,
Hui-ping
Liu,
Y.
Chu,
Yu-ting
Chiu,
Tzu-Hsin
Wu,
Li-Hui
Chou,
Yi-Rong
Chen,
Shiu-Feng
Huang
(2013)
Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan
PLoS ONE, 8
-
J.
Sanchez-Torres,
S.
Viteri,
M.
Molina,
R.
Rosell
(2013)
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
Translational lung cancer research, 2 3
-
(
GrazianoP
CardilloG
MancusoA
, et al. Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics. Chest. 2011;140:1354-1356.22045881)
GrazianoP
CardilloG
MancusoA
, et al. Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics. Chest. 2011;140:1354-1356.22045881
GrazianoP
CardilloG
MancusoA
, et al. Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics. Chest. 2011;140:1354-1356.22045881,
GrazianoP
CardilloG
MancusoA
, et al. Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics. Chest. 2011;140:1354-1356.22045881
-
(
KonishiJ
YamazakiK
AzumaM
, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094-5100.15297412)
KonishiJ
YamazakiK
AzumaM
, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094-5100.15297412
KonishiJ
YamazakiK
AzumaM
, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094-5100.15297412,
KonishiJ
YamazakiK
AzumaM
, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094-5100.15297412
-
A.
Rittmeyer,
F.
Barlesi,
D.
Waterkamp,
Keunchil
Park,
F.
Ciardiello,
J.
Pawel,
S.
Gadgeel,
T.
Hida,
D.
Kowalski,
M.
Dols,
D.
Cortinovis,
J.
Leach,
J.
Polikoff,
C.
Barrios,
F.
Kabbinavar,
O.
Frontera,
F.
Marinis,
H.
Turna,
Jong-Seok
Lee,
M.
Ballinger,
M.
Kowanetz,
P.
He,
Daniel
Chen,
A.
Sandler,
D.
Gandara
(2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet, 389
-
N.
Lindeman,
P.
Cagle,
M.
Beasley,
D.
Chitale,
S.
Dacic,
G.
Giaccone,
R.
Jenkins,
D.
Kwiatkowski,
J.
Saldivar,
J.
Squire,
E.
Thunnissen,
M.
Ladanyi
(2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Journal of Thoracic Oncology, 8
-
(
SocinskiMA
JotteRM
CappuzzoF
, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.29863955)
SocinskiMA
JotteRM
CappuzzoF
, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.29863955
SocinskiMA
JotteRM
CappuzzoF
, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.29863955,
SocinskiMA
JotteRM
CappuzzoF
, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.29863955
-
F.
Bray,
J.
Ferlay,
I.
Soerjomataram,
R.
Siegel,
Lindsey
Torre,
A.
Jemal
(2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA: A Cancer Journal for Clinicians, 68
-
(
SodaM
ChoiYL
EnomotoM
, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.17625570)
SodaM
ChoiYL
EnomotoM
, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.17625570
SodaM
ChoiYL
EnomotoM
, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.17625570,
SodaM
ChoiYL
EnomotoM
, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.17625570
-
H.
Borghaei,
L.
Paz-Ares,
L.
Horn,
D.
Spigel,
M.
Steins,
N.
Ready,
L.
Chow,
E.
Vokes,
E.
Felip,
E.
Holgado,
F.
Barlesi,
M.
Kohlhäufl,
O.
Arrieta,
M.
Burgio,
J.
Fayette,
H.
Léna,
E.
Poddubskaya,
D.
Gerber,
S.
Gettinger,
C.
Rudin,
N.
Rizvi,
L.
Crinò,
G.
Blumenschein,
S.
Antonia,
C.
Dorange,
C.
Harbison,
F.
Finckenstein,
J.
Brahmer
(2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 17
-
J.
Konishi,
K.
Yamazaki,
M.
Azuma,
I.
Kinoshita,
H.
Dosaka-akita,
M.
Nishimura
(2004)
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
Clinical Cancer Research, 10
-
(
SolomonBJ
MokT
KimDW
, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (Published erratum appears in N Engl J Med. 2015; 373:1582). N Engl J Med. 2014;371:2167-2177.25470694)
SolomonBJ
MokT
KimDW
, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (Published erratum appears in N Engl J Med. 2015; 373:1582). N Engl J Med. 2014;371:2167-2177.25470694
SolomonBJ
MokT
KimDW
, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (Published erratum appears in N Engl J Med. 2015; 373:1582). N Engl J Med. 2014;371:2167-2177.25470694,
SolomonBJ
MokT
KimDW
, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (Published erratum appears in N Engl J Med. 2015; 373:1582). N Engl J Med. 2014;371:2167-2177.25470694
-
Amanda
Pilling,
Jihye
Kim,
A.
Estrada-Bernal,
Qiong
Zhou,
A.
Le,
Katherine
Singleton,
L.
Heasley,
A.
Tan,
J.
DeGregori,
R.
Doebele
(2018)
ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
Oncotarget, 9
-
L.
Schmidt,
A.
Kümmel,
D.
Görlich,
M.
Mohr,
S.
Bröckling,
Jan-Henrik
Mikesch,
I.
Grünewald,
A.
Marra,
A.
Schultheis,
E.
Wardelmann,
C.
Müller-Tidow,
T.
Spieker,
C.
Schliemann,
W.
Berdel,
R.
Wiewrodt,
W.
Hartmann
(2015)
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
PLoS ONE, 10
-
(
Sánchez-TorresJM
ViteriS
MolinaMA
RosellR.
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2:244-250.25806238)
Sánchez-TorresJM
ViteriS
MolinaMA
RosellR.
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2:244-250.25806238
Sánchez-TorresJM
ViteriS
MolinaMA
RosellR.
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2:244-250.25806238,
Sánchez-TorresJM
ViteriS
MolinaMA
RosellR.
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2:244-250.25806238
-
R.
Thompson,
S.
Kuntz,
B.
Leibovich,
Haidong
Dong,
C.
Lohse,
W.
Webster,
S.
Sengupta,
I.
Frank,
A.
Parker,
H.
Zincke,
M.
Blute,
T.
Sebo,
J.
Cheville,
E.
Kwon
(2006)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
Cancer research, 66 7
-
A.
Shaw,
S.
Ou,
Y.
Bang,
D.
Camidge,
B.
Solomon,
R.
Salgia,
Gregory
Riely,
M.
Varella-Garcia,
G.
Shapiro,
D.
Costa,
R.
Doebele,
L.
Le,
Zongli
Zheng,
Weiwei
Tan,
P.
Stephenson,
S.
Shreeve,
L.
Tye,
J.
Christensen,
K.
Wilner,
Jeffrey
Clark,
A.
Iafrate
(2014)
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
The New England journal of medicine, 371 21
-
(
RimkunasVM
CrosbyKE
LiD
, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-4457.22661537)
RimkunasVM
CrosbyKE
LiD
, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-4457.22661537
RimkunasVM
CrosbyKE
LiD
, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-4457.22661537,
RimkunasVM
CrosbyKE
LiD
, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-4457.22661537
-
(
MarchettiA
FelicioniL
MalatestaS
, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.21825258)
MarchettiA
FelicioniL
MalatestaS
, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.21825258
MarchettiA
FelicioniL
MalatestaS
, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.21825258,
MarchettiA
FelicioniL
MalatestaS
, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.21825258
-
R.
Herbst,
P.
Baas,
Dong-Wan
Kim,
E.
Felip,
J.
Pérez-Gracia,
Ji-Youn
Han,
J.
Molina,
Joo‐Hang
Kim,
C.
Arvis,
M.
Ahn,
M.
Majem,
M.
Fidler,
G.
Castro,
M.
Garrido,
G.
Lubiniecki,
Shentu
Yue,
E.
Im,
M.
Dolled-Filhart,
E.
Garon
(2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet, 387
-
O.
Melaiu,
Marco
Mina,
M.
Chierici,
R.
Boldrini,
Giuseppe
Jurman,
P.
Romania,
V.
D’Alicandro,
M.
Benedetti,
A.
Castellano,
Tao
Liu,
Cesare
Furlanello,
F.
Locatelli,
D.
Fruci
(2017)
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Clinical Cancer Research, 23
-
(
JohungKL
YehN
DesaiNB
, et al. Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34:123-129.26438117)
JohungKL
YehN
DesaiNB
, et al. Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34:123-129.26438117
JohungKL
YehN
DesaiNB
, et al. Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34:123-129.26438117,
JohungKL
YehN
DesaiNB
, et al. Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34:123-129.26438117
-
(
ShawAT
OuSH
BangYJ
, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.25264305)
ShawAT
OuSH
BangYJ
, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.25264305
ShawAT
OuSH
BangYJ
, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.25264305,
ShawAT
OuSH
BangYJ
, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.25264305
-
(
AtsavesV
TsesmetzisN
ChioureasD
, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633-1637.28344319)
AtsavesV
TsesmetzisN
ChioureasD
, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633-1637.28344319
AtsavesV
TsesmetzisN
ChioureasD
, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633-1637.28344319,
AtsavesV
TsesmetzisN
ChioureasD
, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633-1637.28344319
-
(
KanedaH
OkamotoI
NakagawaK.
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement–positive non–small-cell lung cancer. J Thorac Oncol. 2013;8:e32-33.)
KanedaH
OkamotoI
NakagawaK.
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement–positive non–small-cell lung cancer. J Thorac Oncol. 2013;8:e32-33.
KanedaH
OkamotoI
NakagawaK.
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement–positive non–small-cell lung cancer. J Thorac Oncol. 2013;8:e32-33.,
KanedaH
OkamotoI
NakagawaK.
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement–positive non–small-cell lung cancer. J Thorac Oncol. 2013;8:e32-33.
-
J.
Mazières,
G.
Zalcman,
L.
Crinò,
P.
Biondani,
F.
Barlesi,
T.
Filleron,
A.
Dingemans,
H.
Léna,
I.
Monnet,
S.
Rothschild,
F.
Cappuzzo,
B.
Besse,
L.
Thiberville,
D.
Rouvière,
R.
Dziadziuszko,
E.
Smit,
J.
Wolf,
C.
Spirig,
N.
Pécuchet,
F.
Leenders,
J.
Heuckmann,
J.
Diebold,
J.
Milia,
Roman
Thomas,
O.
Gautschi
(2015)
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 9
-
(
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.30207593)
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.30207593
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.30207593,
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.30207593
-
T.
Nomi,
M.
Sho,
T.
Akahori,
K.
Hamada,
A.
Kubo,
H.
Kanehiro,
Shinji
Nakamura,
K.
Enomoto,
H.
Yagita,
M.
Azuma,
Y.
Nakajima
(2007)
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Clinical Cancer Research, 13
-
S.
Vareki
(2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Journal for Immunotherapy of Cancer, 6
-
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline
-
(
LeighlNB
RekhtmanN
BiermannWA
, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32:3673-3679.25311215)
LeighlNB
RekhtmanN
BiermannWA
, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32:3673-3679.25311215
LeighlNB
RekhtmanN
BiermannWA
, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32:3673-3679.25311215,
LeighlNB
RekhtmanN
BiermannWA
, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32:3673-3679.25311215
-
(
CaoB
WeiP
LiuZ
, et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther. 2016;9:131-138.26770062)
CaoB
WeiP
LiuZ
, et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther. 2016;9:131-138.26770062
CaoB
WeiP
LiuZ
, et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther. 2016;9:131-138.26770062,
CaoB
WeiP
LiuZ
, et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther. 2016;9:131-138.26770062
-
M.
Socinski,
R.
Jotte,
F.
Cappuzzo,
F.
Orlandi,
D.
Stroyakovskiy,
N.
Nogami,
D.
Rodríguez-Abreu,
D.
Moro-Sibilot,
C.
Thomas,
F.
Barlesi,
G.
Finley,
C.
Kelsch,
Anthony
Lee,
S.
Coleman,
Y.
Deng,
Yijing
Shen,
M.
Kowanetz,
A.
López-Chávez,
A.
Sandler,
M.
Reck
(2018)
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
The New England Journal of Medicine, 378
-
(
KwakEL
BangYJ
CamidgeDR
, et al. Anaplastic lymphoma kinase inhibition in non- small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.20979469)
KwakEL
BangYJ
CamidgeDR
, et al. Anaplastic lymphoma kinase inhibition in non- small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.20979469
KwakEL
BangYJ
CamidgeDR
, et al. Anaplastic lymphoma kinase inhibition in non- small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.20979469,
KwakEL
BangYJ
CamidgeDR
, et al. Anaplastic lymphoma kinase inhibition in non- small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.20979469
-
E.
Kim,
A.
Kim,
S.
Kim,
Y.
Chang
(2017)
MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Lung cancer, 110
-
(
CamidgeDR
BangYJ
KwakEL
, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019.22954507)
CamidgeDR
BangYJ
KwakEL
, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019.22954507
CamidgeDR
BangYJ
KwakEL
, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019.22954507,
CamidgeDR
BangYJ
KwakEL
, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019.22954507
-
(
PetersS
CamidgeR
ShawAT
, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829-838.28586279)
PetersS
CamidgeR
ShawAT
, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829-838.28586279
PetersS
CamidgeR
ShawAT
, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829-838.28586279,
PetersS
CamidgeR
ShawAT
, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829-838.28586279
-
(
WuYC
ChangIC
WangCL
, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE. 2013;8:e70839.23951022)
WuYC
ChangIC
WangCL
, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE. 2013;8:e70839.23951022
WuYC
ChangIC
WangCL
, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE. 2013;8:e70839.23951022,
WuYC
ChangIC
WangCL
, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE. 2013;8:e70839.23951022
-
(
IlieM
HofmanV
DietelM
SoriaJC
HofmanP.
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468:511-525.26915032)
IlieM
HofmanV
DietelM
SoriaJC
HofmanP.
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468:511-525.26915032
IlieM
HofmanV
DietelM
SoriaJC
HofmanP.
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468:511-525.26915032,
IlieM
HofmanV
DietelM
SoriaJC
HofmanP.
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468:511-525.26915032
-
(
RizviNA
HellmannMD
SnyderA
, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124-128.25765070)
RizviNA
HellmannMD
SnyderA
, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124-128.25765070
RizviNA
HellmannMD
SnyderA
, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124-128.25765070,
RizviNA
HellmannMD
SnyderA
, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124-128.25765070
-
P.
Tomasini,
L.
Greillier,
Arnaud
Boyer,
Arnaud
Jeanson,
F.
Barlesi
(2018)
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
Journal of thoracic disease, 10 Suppl 9
-
M.
Soda,
Y.
Choi,
M.
Enomoto,
S.
Takada,
Y.
Yamashita,
S.
Ishikawa,
Shin-ichiro
Fujiwara,
Hideki
Watanabe,
K.
Kurashina,
H.
Hatanaka,
M.
Bando,
S.
Ohno,
Y.
Ishikawa,
H.
Aburatani,
T.
Niki,
Y.
Sohara,
Y.
Sugiyama,
H.
Mano
(2007)
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Nature, 448
-
(
El-TelbanyA
MaPC.
Cancer genes in lung cancer: racial disparities: are there any. Genes Cancer. 2012;3:467-480.23264847)
El-TelbanyA
MaPC.
Cancer genes in lung cancer: racial disparities: are there any. Genes Cancer. 2012;3:467-480.23264847
El-TelbanyA
MaPC.
Cancer genes in lung cancer: racial disparities: are there any. Genes Cancer. 2012;3:467-480.23264847,
El-TelbanyA
MaPC.
Cancer genes in lung cancer: racial disparities: are there any. Genes Cancer. 2012;3:467-480.23264847
-
(
NomiT
ShoM
AkahoriT
, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157.17404099)
NomiT
ShoM
AkahoriT
, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157.17404099
NomiT
ShoM
AkahoriT
, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157.17404099,
NomiT
ShoM
AkahoriT
, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157.17404099
-
(
LindemanNI
CaglePT
BeasleyMB
, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828-860.23551194)
LindemanNI
CaglePT
BeasleyMB
, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828-860.23551194
LindemanNI
CaglePT
BeasleyMB
, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828-860.23551194,
LindemanNI
CaglePT
BeasleyMB
, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828-860.23551194
-
D.
Camidge,
Y.
Bang,
E.
Kwak,
A.
Iafrate,
M.
Varella-Garcia,
S.
Fox,
Gregory
Riely,
B.
Solomon,
S.
Ou,
Dong-Wan
Kim,
R.
Salgia,
P.
Fidias,
J.
Engelman,
L.
Gandhi,
P.
Jänne,
D.
Costa,
G.
Shapiro,
P.
LoRusso,
K.
Ruffner,
P.
Stephenson,
Yiyun
Tang,
K.
Wilner,
Jeffrey
Clark,
A.
Shaw
(2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
The Lancet. Oncology, 13 10
-
(
MazièresJ
ZalcmanG
CrinòL
, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.25667280)
MazièresJ
ZalcmanG
CrinòL
, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.25667280
MazièresJ
ZalcmanG
CrinòL
, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.25667280,
MazièresJ
ZalcmanG
CrinòL
, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.25667280
-
Jin
Kang,
Hua-jun
Chen,
Xuchao
Zhang,
J.
Su,
Qing
Zhou,
H.
Tu,
Zhen
Wang,
Bin-chao
Wang,
W.
Zhong,
Xue-Ning
Yang,
Zhi-hong
Chen,
Yan
Ding,
Xue
Wu,
Mei
Wang,
Jian-Gang
Fu,
Zhenfan
Yang,
Xian
Zhang,
Y.
Shao,
Yi-long
Wu,
Jin-Ji
Yang
(2018)
Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
Thoracic Cancer, 9
-
(
ThompsonRH
KuntzSM
LeibovichBC
, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-3385.16585157)
ThompsonRH
KuntzSM
LeibovichBC
, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-3385.16585157
ThompsonRH
KuntzSM
LeibovichBC
, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-3385.16585157,
ThompsonRH
KuntzSM
LeibovichBC
, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-3385.16585157
-
(
PillingAB
KimJ
Estrada-BernalA
, et al. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 2018;9:8823-8835.29507657)
PillingAB
KimJ
Estrada-BernalA
, et al. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 2018;9:8823-8835.29507657
PillingAB
KimJ
Estrada-BernalA
, et al. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 2018;9:8823-8835.29507657,
PillingAB
KimJ
Estrada-BernalA
, et al. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 2018;9:8823-8835.29507657
-
(
ChenS
XuY
ChenY
, et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS ONE. 2012;7:e36326.22615765)
ChenS
XuY
ChenY
, et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS ONE. 2012;7:e36326.22615765
ChenS
XuY
ChenY
, et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS ONE. 2012;7:e36326.22615765,
ChenS
XuY
ChenY
, et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS ONE. 2012;7:e36326.22615765
-
Chen
Lin,
Xun
Shi,
Shao-Fen
Yang,
Jun
Zhao,
Qiong
He,
Ying
Jin,
Xinmin
Yu
(2019)
Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lung cancer, 131
-
(2015)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.
The New England journal of medicine, 373 16
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
(
AntoniaSJ
VillegasA
DanielD
, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.28885881)
AntoniaSJ
VillegasA
DanielD
, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.28885881
AntoniaSJ
VillegasA
DanielD
, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.28885881,
AntoniaSJ
VillegasA
DanielD
, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.28885881
-
F.
Hirsch,
K.
Suda,
Jacinta
Wiens,
P.
Bunn
(2016)
New and emerging targeted treatments in advanced non-small-cell lung cancer
The Lancet, 388
-
A.
Tsao
(2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Yearbook of Oncology, 2012
-
(
TakeuchiK
SodaM
TogashiY
, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.22327623)
TakeuchiK
SodaM
TogashiY
, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.22327623
TakeuchiK
SodaM
TogashiY
, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.22327623,
TakeuchiK
SodaM
TogashiY
, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.22327623
-
(
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387:1540-1550.26712084)
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387:1540-1550.26712084
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387:1540-1550.26712084,
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387:1540-1550.26712084
-
(
KangJ
ChenHJ
ZhangXC
, et al. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. Thorac Cancer. 2018;9:1093-1103.29978950)
KangJ
ChenHJ
ZhangXC
, et al. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. Thorac Cancer. 2018;9:1093-1103.29978950
KangJ
ChenHJ
ZhangXC
, et al. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. Thorac Cancer. 2018;9:1093-1103.29978950,
KangJ
ChenHJ
ZhangXC
, et al. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. Thorac Cancer. 2018;9:1093-1103.29978950
-
Cuiling
Zhou,
Jianjun
Tang,
Huanhuan
Sun,
Xiaobin
Zheng,
Zhanyu
Li,
Tiantian
Sun,
J.
Li,
Shuncong
Wang,
Xiuling
Zhou,
Hongliu
Sun,
Zhibin
Cheng,
Hongyu
Zhang,
Haiqing
Ma
(2017)
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer
Oncotarget, 8
-
R.
Hino,
K.
Kabashima,
Y.
Kato,
H.
Yagi,
Motonobu
Nakamura,
T.
Honjo,
Taku
Okazaki,
Y.
Tokura
(2010)
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
Cancer, 116
-
(
CaseySC
TongL
LiY
, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227-231.26966191)
CaseySC
TongL
LiY
, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227-231.26966191
CaseySC
TongL
LiY
, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227-231.26966191,
CaseySC
TongL
LiY
, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227-231.26966191
-
(
OoiAT
GowerAC
ZhangKX
, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila). 2014;7:487-495.24618292)
OoiAT
GowerAC
ZhangKX
, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila). 2014;7:487-495.24618292
OoiAT
GowerAC
ZhangKX
, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila). 2014;7:487-495.24618292,
OoiAT
GowerAC
ZhangKX
, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila). 2014;7:487-495.24618292
-
Cuiling
Zhou,
G.
Che,
Xiaobin
Zheng,
J.
Qiu,
Zhinan
Xie,
Yunyan
Cong,
Xiaofeng
Pei,
Hongyu
Zhang,
Huanhuan
Sun,
Haiqing
Ma
(2019)
Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer
Journal of Cancer Research and Clinical Oncology, 145
-
E.
Akbay,
E.
Akbay,
S.
Koyama,
J.
Carretero,
Abigail
Altabef,
Abigail
Altabef,
J.
Tchaicha,
J.
Tchaicha,
Camilla
Christensen,
Camilla
Christensen,
Oliver
Mikse,
Oliver
Mikse,
A.
Cherniack,
Ellen
Beauchamp,
Trevor
Pugh,
M.
Wilkerson,
P.
Fecci,
M.
Butaney,
J.
Reibel,
J.
Reibel,
Margaret
Soucheray,
Travis
Cohoon,
Travis
Cohoon,
P.
Jänne,
M.
Meyerson,
M.
Meyerson,
D.
Hayes,
Geoffrey
Shapiro,
T.
Shimamura,
L.
Sholl,
S.
Rodig,
G.
Freeman,
P.
Hammerman,
G.
Dranoff,
Kwok-kin
Wong
(2013)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Cancer discovery, 3 12
-
(
Maleki VarekiS
. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6:157.30587233)
Maleki VarekiS
. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6:157.30587233
Maleki VarekiS
. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6:157.30587233,
Maleki VarekiS
. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6:157.30587233
-
(
MokTS
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.30955977)
MokTS
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.30955977
MokTS
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.30955977,
MokTS
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.30955977
-
(
AkbayEA
KoyamaS
CarreteroJ
, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355-1363.24078774)
AkbayEA
KoyamaS
CarreteroJ
, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355-1363.24078774
AkbayEA
KoyamaS
CarreteroJ
, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355-1363.24078774,
AkbayEA
KoyamaS
CarreteroJ
, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355-1363.24078774
-
K.
Johung,
Norman
Yeh,
N.
Desai,
T.
Williams,
T.
Lautenschlaeger,
Nils
Arvold,
M.
Ning,
A.
Attia,
C.
Lovly,
S.
Goldberg,
K.
Beal,
James
Yu,
B.
Kavanagh,
V.
Chiang,
D.
Camidge,
J.
Contessa
(2016)
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 2
-
A.
Marchetti,
L.
Felicioni,
S.
Malatesta,
Maria
Sciarrotta,
L.
Guetti,
A.
Chella,
P.
Viola,
Carmela
Pullara,
F.
Mucilli,
F.
Buttitta
(2011)
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 26
-
Bing
Cao,
P.
Wei,
Zebing
Liu,
R.
Bi,
Yong-ming
Lu,
Ling
Zhang,
Jing
Zhang,
Yu-si
Yang,
Chen
Shen,
Xiang
Du,
Xiaoyan
Zhou
(2015)
Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features
OncoTargets and therapy, 9
-
(
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.27979383)
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.27979383
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.27979383,
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.27979383
-
E.
Kwak,
Y.
Bang,
D.
Camidge,
A.
Shaw,
B.
Solomon,
Robert
Maki,
Sai-Hong
Ou,
Bruce
Dezube,
P.
Jänne,
Daniel,
B.
Costa,
M.
Varella-Garcia,
W.
Kim,
Thomas
Lynch,
P.
Fidias,
Hannah
Stubbs,
J.
Engelman,
V.
Lecia,
Sequist,
Weiwei
Tan,
L.
Gandhi,
M.
Mino‐Kenudson,
Greg
Wei,
S.
Shreeve,
M.
Ratain,
Jeffrey,
Settleman,
James
Christensen,
D.
Haber,
K.
Wilner,
R.
Salgia,
Geoffrey
Shapiro,
J.
Clark,
A.
Iafrate
(2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
The New England journal of medicine, 363 18
-
(
MinutiG
D’InceccoA
LandiL
CappuzzoF.
Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15:1203-1213.24745764)
MinutiG
D’InceccoA
LandiL
CappuzzoF.
Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15:1203-1213.24745764
MinutiG
D’InceccoA
LandiL
CappuzzoF.
Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15:1203-1213.24745764,
MinutiG
D’InceccoA
LandiL
CappuzzoF.
Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15:1203-1213.24745764
-
(
MelaiuO
MinaM
ChiericiM
, et al. PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and combined with HLA class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res. 2017;23:4462-4472.28270499)
MelaiuO
MinaM
ChiericiM
, et al. PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and combined with HLA class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res. 2017;23:4462-4472.28270499
MelaiuO
MinaM
ChiericiM
, et al. PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and combined with HLA class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res. 2017;23:4462-4472.28270499,
MelaiuO
MinaM
ChiericiM
, et al. PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and combined with HLA class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res. 2017;23:4462-4472.28270499